Trials / Completed
CompletedNCT02757989
Allogeneic Hematopoietic Stem Cell Transplantation in Patients With Myelodysplastic Syndrome Low Risk
Allogeneic Hematopoietic Stem Cell Transplantation in Patients With Low or Intermediate-1 Myelodysplastic Syndrome: A Prospective Multicenter Phase II Study Based on Donor Availability on Behalf of the GFM & SFGM-TC
- Status
- Completed
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 79 (actual)
- Sponsor
- Groupe Francophone des Myelodysplasies · Academic / Other
- Sex
- All
- Age
- 18 Years – 69 Years
- Healthy volunteers
- Not accepted
Summary
Comparison of survival in patients with or without a matched donor at 36 months
Detailed description
Patients with a matched donor (8/8 at molecular level unrelated donor or matched sibling) received an allogeneic hematopoietic stem cell transplantation. Patients without a matched donor received the best available treatment. All patients will be followed at least 36 months or until the end of the study.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| OTHER | transplantation | allogeneic hematopoietic stem cell transplantation in patients with donor |
Timeline
- Start date
- 2016-05-31
- Primary completion
- 2024-06-07
- Completion
- 2024-06-07
- First posted
- 2016-05-02
- Last updated
- 2024-08-02
Locations
37 sites across 1 country: France
Source: ClinicalTrials.gov record NCT02757989. Inclusion in this directory is not an endorsement.